<DOC>
	<DOCNO>NCT00715078</DOCNO>
	<brief_summary>This randomize , multicenter , single blind , Phase 2 trial immunotherapy men metastatic androgen independent prostate cancer evaluate sipuleucel-T manufactured different concentration PA2024 antigen</brief_summary>
	<brief_title>To Evaluate Sipuleucel-T Manufactured With Different Concentrations Prostate Adenocarcinoma ( PA2024 ) Antigen</brief_title>
	<detailed_description>This multicenter , single blind , Phase 2 study . Subjects receive investigational product , sipuleucel-T , manufacture 1 3 different concentration PA2024 antigen . The purpose study compare change CD54 upregulation 3 group subject . The study also evaluate level immune response , length survival , role circulate tumor cell level blood , change quality life 3 group subject . All subject blind cohort assignment ensure unbiased completion quality life ( QOL ) questionnaires . All subject follow study remainder life .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>For subject eligible participation study , follow criterion must satisfy . Histologically document adenocarcinoma prostate . Metastatic disease . Progressive androgen independent prostate cancer . Serum PSA &gt; = 5.0 ng/mL . Castrate level testosterone ( &lt; 50 ng/dL ) achieve via medical surgical castration . Men &gt; = 18 year age . Adequate hematologic , renal liver function . In order ensure integrity study data maintain , study participant must able complete study visit . For reason , study participation limit live permanent residence within comfortable drive distance ( roundtrip within one day ) clinical research site . A subject eligible participation study follow criterion apply . The presence know lung , liver , brain metastasis , malignant pleural effusion , malignant ascites . A requirement treatment opioid analgesic reason within 21 day prior registration . Moderate severe disease relate pain . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; = 2 . Use nonsteroidal antiandrogens within 6 week registration . Antiandrogen withdrawal response . Treatment chemotherapy within 3 month registration . More 2 chemotherapy regimen prior registration . Initiation discontinuation bisphosphonate therapy within 28 day prior registration . Treatment follow medication intervention within 28 day registration : Systemic corticosteroid , External beam radiation therapy surgery , Dietary herbal supplement , well alternative treatment evidence hormonal and/or anticancer property ( e.g. , PCSPES PCSPEC ) saw palmetto , Megestrol acetate ( Megace ( R ) ) , diethylstilbesterol ( DES ) , cyproterone acetate , ++Ketoconazole , 5alphareductase inhibitor , High dose calcitriol [ 1,25 ( OH ) 2Vitamin D ] ( i.e. , &gt; 0.5 mg/day ) . Any systemic therapy prostate cancer ( except medical castration ) . Treatment investigational vaccine within 2 year registration treatment investigational product within 28 day registration . Participation previous study involve sipuleucelT , regardless whether subject receive sipuleucelT ( APC8015 ) placebo . Known pathologic longbone fracture , imminent pathologic longbone fracture ( cortical erosion radiography &gt; 50 % ) spinal cord compression . A history stage III great cancer , exclude prostate cancer . Basal squamous cell skin cancer must adequately treated subject must diseasefree time registration . Subjects history stage I II cancer must adequately treated diseasefree &gt; = 3 year time registration . A requirement systemic immunosuppressive therapy reason . A history allergic reaction attribute compound similar chemical biologic composition sipuleucelT granulocytemacrophage colonystimulating factor ( GMCSF ) . Any infection require parenteral antibiotic therapy cause fever ( temp &gt; 100.5°F &gt; 38.1°C ) within 1 week prior registration . Any medical intervention condition , opinion Principal Investigator Dendreon Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>prostate specific antigen ( PSA )</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
</DOC>